In an ongoing effort to systematically assess novel antineoplastic drugs, in particular novel drug combinations, for their potential as ES therapeutics, we found inhibitors of class I/II histone deacetylases (Sonnemann et al. 2007) as well as modulators of sirtuins (Sonnemann et al. 2016; Marx et al. 2018), activators of wild-type p53 (Sonnemann et al. 2011) and inhibitors of polo-like kinase 4 (Kerschner-Morales et al. 2020) to be effective against ES in vitro. The gene discussed is TP53; the disease is Ewing sarcoma.